Companies across the globe are working toward the development of new treatment therapies for Herpes Zoster, Future goals include developing new vaccines for specific groups, such as immunocompromised individuals, and developing an evidence base on which type of immunocompromised individuals can be safely and effectively vaccinated with a live-attenuated vaccine.
Some of the key companies in the Herpes Zoster therapeutics market include Nobelpharma, GC Pharma, and EyeGene are involved in developing therapies for Herpes Zoster. The emerging therapies in the pipeline include NPC-06 (Nobelpharma), CRV-101 (GC Pharma), EG-HZ (EyeGene), and others.
“Herpes Zoster Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Herpes Zoster Market.
The Herpes Zoster Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Herpes Zoster Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the emerging therapies for the treatment of Herpes Zoster and the aggregate therapies developed by major pharma companies.
-
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.
-
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Herpes Zoster market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Analysis of Emerging Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
-
Late stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Route of Administration
Herpes Zoster pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
-
Intra-articular
-
Intraocular
-
Intrathecal
-
Intravenous
-
Ophthalmic
-
Oral
-
Parenteral
-
Subcutaneous
-
Topical
-
Transdermal
Molecule Type
Products have been categorized under various Molecule types, such as
-
Oligonucleotide
-
Peptide
-
Small molecule
Learn How the Ongoing Clinical & Commercial Activities will Affect the Herpes Zoster Therapeutic Segment @
https://www.delveinsight.com/sample-request/herpes-zoster-pipeline-insight
Herpes Zoster Therapeutics Landscape
Several major pharma and biotech giants are developing therapies for Herpes Zoster. Currently, Curevo Inc. is leading the therapeutics market with its Herpes Zoster drug candidates in the most advanced stage of clinical development.
The Leading Companies in the Herpes Zoster Therapeutics Market Include:
AIM Vaccine, Akshaya Bio, CPL Biologicals, Curevo Vaccine, Dynavax Technologies, Enzolytics, EuBiologics, EyeGene, Gene One Life Science, GlaxoSmithKline, HilleVax, Inc., Merck Sharp & Dohme Corp, NAL Pharma, NanoViricides, Nobelpharma, Pfizer, Shulov Innovative Science, Shulov Institute for Science LTD., Turn therapeutics, Vaccitech, Vapogenix, XBiotech, and others.
Herpes Zoster Emerging and Marketed Drugs Covered in the Report Include:
-
CRV-101: Curevo Inc.
-
EG-HZ: EyeGene
-
NPC-06:Nobelpharma
-
Shingrix: GlaxoSmithKline
-
VARIVAX: Merck Sharp & Dohme Corp
-
ZEP-3: Shulov Institute for Science LTD.
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @
https://www.delveinsight.com/sample-request/herpes-zoster-pipeline-insight
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Herpes Zoster Current Treatment Patterns
4. Herpes Zoster – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Herpes Zoster Late Stage Products (Phase-III)
7. Herpes Zoster Mid-Stage Products (Phase-II)
8. Herpes Zoster Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Herpes Zoster Discontinued Products
13. Herpes Zoster Product Profiles
14. Key Companies in the Herpes Zoster Market
15. Key Products in the Herpes Zoster Therapeutics Segment
16. Dormant and Discontinued Products
17. Herpes Zoster Unmet Needs
18. Herpes Zoster Future Perspectives
19. Herpes Zoster Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
https://www.delveinsight.com/sample-request/herpes-zoster-pipeline-insight
Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/